当前位置: X-MOL 学术Blood Cancer J. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.
Blood Cancer Journal ( IF 12.9 ) Pub Date : 2021-09-03 , DOI: 10.1038/s41408-021-00545-w
Karthik Ramasamy 1 , Ajay Nooka 2 , Hang Quach 3 , Myo Htut 4 , Rakesh Popat 5 , Michaela Liedtke 6 , Sascha A Tuchman 7 , Jacob Laubach 8 , Cristina Gasparetto 9 , Asher Chanan-Khan 10 , Mark Hertzberg 11 , Mark deMario 12 , Eveline Nueesch 13 , Evelyne Chesne 13 , Izolda Franjkovic 14 , Katharina Lechner 14 , Martin Kornacker 13 , Hearn Jay Cho 15, 16
Affiliation  



中文翻译:

BET 抑制剂 RO6870810 在晚期多发性骨髓瘤患者中的 1b 期剂量递增/扩展研究。

更新日期:2021-09-03
down
wechat
bug